uniQure Announces Leadership Promotions and Executive Transition
August 20 2019 - 7:00AM
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced the promotions of Sander van Deventer, M.D.,
Ph.D., to Executive Vice President, Research and Product
Development, and Alex Kuta, Ph.D., to Executive Vice President,
Operations, effective immediately. As a result of these
changes, the Company is eliminating the Chief Operating Officer
role, and Scott McMillan, Ph.D., will be retiring from uniQure.
“With the promotions of Sander and Alex, we are
recognizing the demonstrated track-records and exceptional
leadership that each has provided as we advance uniQure’s pipeline
of novel gene therapies,” stated Matt Kapusta, chief executive
officer of uniQure. “As an original founder of uniQure, Sander is a
renowned industry expert who has developed an exceptional research
team and expanded our proprietary pipeline of investigational AAV
gene therapies. Alex has spearheaded and achieved remarkable
regulatory successes for our hemophilia and Huntington’s disease
programs. We very much look forward to their continued
contributions as we progress AMT-061 for the treatment of
hemophilia B towards our planned regulatory submissions and expect
to advance AMT-130 into the clinic for the treatment of
Huntington’s disease. I also would like to thank Scott for his
important contributions to uniQure over the past two years. Scott
has played an important role in significantly strengthening our
industry-leading CMC capabilities, and I wish him all the best in
the future.”
In Dr. van Deventer’s new role as Executive Vice
President, Research and Product Development, he is responsible for
the Company’s gene therapy research activities, as well as
nonclinical development, process development, analytical
development and vector development. Dr. van Deventer will
continue to serve as General Manager of uniQure’s Amsterdam
research and technology center of excellence. In Dr. Kuta’s
new role as Executive Vice President, Operations, he is responsible
for global quality and regulatory affairs, as well as GMP
manufacturing at uniQure’s state-of-the-art facility in Lexington,
Massachusetts.
Dr. van Deventer joined uniQure as Chief
Scientific Officer and General Manager, Amsterdam in August 2017
and is a leading pioneer in the biotechnology industry and in the
field of gene therapy. He was a co-founder of uniQure's predecessor
Amsterdam Molecular Therapeutics (AMT) in 1998 and previously
served on uniQure’s board of directors. Dr. van Deventer is
currently Operating Partner at Forbion Capital partners and
Professor of Translational Gastroenterology at Leiden University
Medical Center. He also serves as member of the Board for Hookipa
Pharma Inc. in Vienna, Austria. Dr. van Deventer is a trained
internist and board-certified gastroenterologist. He received a
Ph.D. from the University of Amsterdam.
Dr. Kuta joined uniQure in January 2017 as
Senior Vice President, Regulatory Affairs with more than 30 years
in the biotechnology field. His previous experiences include senior
roles at EMD Serono, AMAG Pharmaceuticals and Genzyme Corporation,
where Dr. Kuta served for 15 years in regulatory leadership
positions of increasing responsibility. Prior to joining
industry, he was Chief of the Cytokine and Gene Therapy Branch in
the Center for Biologics at FDA. Dr. Kuta has also served as a
member of the BIO Regulatory Affairs Leadership Committee, Cell and
Gene Therapy Working Group and the ICH Gene Therapy Working Group.
Dr. Kuta holds a Bachelor of Science degree from Saint John's
University and a Ph.D. from Chicago Medical School at Rosalind
Franklin U-Med & Science. He conducted his post-doctoral
studies at the National Cancer Institute/ National Institutes of
Health.
About uniQure uniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary gene therapies to treat patients with hemophilia B,
hemophilia A, Huntington's disease, Fabry disease, spinocerebellar
ataxia Type 3 and other diseases. www.uniQure.com
uniQure Forward-Looking
StatementsThis press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as "anticipate," "believe," "could," "estimate," "expect,"
"goal," "intend," "look forward to", "may," "plan," "potential,"
"predict," "project," "should," "will," "would" and similar
expressions. Forward-looking statements are based on management's
beliefs and assumptions and on information available to management
only as of the date of this press release. These forward-looking
statements include, but are not limited to, our ability to file any
planned regulatory submissions for AMT-061 or any product, our
ability to advance AMT-130 into the clinic for the treatment of
Huntington’s disease, our ability to achieve any of our other
planned near term or other milestones, the risk of cessation, delay
or lack of success of any of our ongoing or planned clinical
studies, and/or the development and regulatory approval of our
product candidates. Our actual results could differ materially from
those anticipated in these forward-looking statements for many
reasons, including, without limitation, risks associated with our
and our collaborators’ clinical development activities, clinical
results, collaboration arrangements, corporate reorganizations and
strategic shifts, regulatory oversight, product commercialization
and intellectual property claims, as well as the risks,
uncertainties and other factors described under the heading "Risk
Factors" in uniQure’s Quarterly Report on Form 10-Q filed on July
29, 2019. Given these risks, uncertainties and other factors, you
should not place undue reliance on these forward-looking
statements, and we assume no obligation to update these
forward-looking statements, even if new information becomes
available in the future.
uniQure Contacts: |
|
|
|
|
|
FOR INVESTORS: |
|
FOR MEDIA: |
|
|
|
Maria E. Cantor |
Eva M. Mulder |
Tom Malone |
Direct: 339-970-7536 |
Direct: +31 20 240 6103 |
Direct: 339-970-7558 |
Mobile: 617-680-9452 |
Mobile: +31 6 52 33 15 79 |
Mobile:339-223-8541 |
m.canto@uniQure.com |
e.mulder@uniQure.com |
t.malone@uniQure.com |
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Mar 2024 to Apr 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Apr 2023 to Apr 2024